Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.
Journal
Signal transduction and targeted therapy
ISSN: 2059-3635
Titre abrégé: Signal Transduct Target Ther
Pays: England
ID NLM: 101676423
Informations de publication
Date de publication:
10 02 2021
10 02 2021
Historique:
received:
21
11
2020
accepted:
15
01
2021
entrez:
11
2
2021
pubmed:
12
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
Treatment of severe Coronavirus Disease 2019 (COVID-19) is challenging. We performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage, based on our phase 1 data. In this randomized, double-blind, and placebo-controlled trial, we recruited 101 severe COVID-19 patients with lung damage. They were randomly assigned at a 2:1 ratio to receive either UC-MSCs (4 × 10
Identifiants
pubmed: 33568628
doi: 10.1038/s41392-021-00488-5
pii: 10.1038/s41392-021-00488-5
pmc: PMC7873662
doi:
Banques de données
ClinicalTrials.gov
['NCT04288102']
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
58Références
Engineering (Beijing). 2020 Oct;6(10):1153-1161
pubmed: 32292627
Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3621-6
pubmed: 26976597
Signal Transduct Target Ther. 2020 Aug 27;5(1):172
pubmed: 32855385
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Med Virol. 2020 Jul;92(7):814-818
pubmed: 32253759
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Front Med. 2020 Oct;14(5):664-673
pubmed: 32761491
Stem Cells Transl Med. 2015 Oct;4(10):1199-213
pubmed: 26285659
Signal Transduct Target Ther. 2020 Jun 10;5(1):89
pubmed: 32533062
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Cell Stem Cell. 2018 Jun 01;22(6):824-833
pubmed: 29859173
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Respir Res. 2014 Apr 04;15:39
pubmed: 24708472
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
Eur J Radiol. 2020 Jun;127:109008
pubmed: 32335426
Lancet Respir Med. 2015 Jan;3(1):24-32
pubmed: 25529339
Aging Dis. 2020 Mar 9;11(2):216-228
pubmed: 32257537
Immunity. 2020 Jul 14;53(1):19-25
pubmed: 32610079
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Nat Commun. 2020 Jul 8;11(1):3410
pubmed: 32641700
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Respir Med. 2019 Feb;7(2):154-162
pubmed: 30455077
N Engl J Med. 2020 Jul 17;:
pubmed: 32678530
Int J Infect Dis. 2020 Jul;96:431-439
pubmed: 32425638
Lancet Respir Med. 2020 Sep;8(9):853-862
pubmed: 32735842
Nat Immunol. 2020 Sep;21(9):1107-1118
pubmed: 32788748